Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2025
Chief Executive Officer 42 15/05/2019
Chief Executive Officer 49 01/01/2023
Director TitleAgeSince
Chairman 63 01/01/2023
Director/Board Member 63 01/01/2023
Director/Board Member 54 01/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%+8.60% - - 504K
+0.55%-1.08%+168.45%+300.55% 17.36B
-1.74%-7.70%-44.51%-25.68% 9.37B
+0.19%+1.65%+29.44%+21.58% 6.79B
-0.17%+3.99% - - 5.09B
-0.39%+0.21%-31.90%-24.73% 5.07B
-2.92%-7.77%-29.69%-31.24% 4.18B
-1.36%-17.61%+62.18%+48.54% 3.81B
-0.72%-13.91%+167.53%-46.54% 3.69B
+0.64%+2.22%-19.35%-42.41% 2.62B
Average -0.99%-3.31%+37.77%+25.01% 6.44B
Weighted average by Cap. -0.46%-2.88%+60.96%+90.15%
Logo Bio Vitos Pharma
Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.
Employees
1
  1. Stock Market
  2. Stocks
  3. BIOVIT Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!